Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 1,900,000 shares, a decline of 15.2% from the June 30th total of 2,240,000 shares. Based on an average trading volume of 950,400 shares, the days-to-cover ratio is currently 2.0 days.
Matinas BioPharma Stock Performance
Shares of NYSEAMERICAN:MTNB opened at $0.17 on Tuesday. The company has a market cap of $41.39 million, a PE ratio of -1.38 and a beta of 1.70. Matinas BioPharma has a 12 month low of $0.11 and a 12 month high of $0.89.
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.03) EPS for the quarter.
Institutional Investors Weigh In On Matinas BioPharma
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Recommended Stories
- Five stocks we like better than Matinas BioPharma
- Investing In Automotive Stocks
- Survey: Top 175 Fittest Retirement Locations in America
- Energy and Oil Stocks Explained
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Investing in the High PE Growth Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.